Skip to content

The STATIN CHOICE Decision Aid for Type 2 Diabetes Patients

The STATIN CHOICE Decision Aid for Type 2 Diabetes Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00548639
Enrollment
152
Registered
2007-10-24
Start date
2007-08-31
Completion date
2010-04-30
Last updated
2019-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

Diabetes is a growing epidemic within the United States that disproportionately affects economically disadvantaged communities like East Harlem. As diabetic patients are at very high risk for heart disease, experts recommend an aggressive approach towards using statins in people with diabetes. However, statins and other helpful drugs are only effective if patients decide to take them. Adherence to this medication is notoriously poor and is aggravated by its required life-long use. This study is designed to test the effectiveness of a new decision aid in helping diverse, inner-city patients with diabetes understand the risks and benefits in taking statins and whether this enhanced decision making process improves their adherence to the medication.

Detailed description

To compare the efficacy of usual consultations with or without the decision aid STATIN CHOICE in type 2 diabetic patients using or considering using statins to lower CV risk in terms of statin use, adherence, knowledge, beliefs and decisional conflict. The study team's primary hypothesis is that 3 months after the index discussion, significantly more patients randomized to STATIN CHOICE are using statins, are adherent to statins, are knowledgeable about the statin choice, and are satisfied with their decision than patients randomized to usual care consultation, and that these benefits will be achieved without deterioration in quality of life.

Interventions

Paper based instrument with pictures indicating level of risk.

OTHERControl Pamphlet

ADA Diabetes Sheet

Sponsors

Mayo Clinic
CollaboratorOTHER
Icahn School of Medicine at Mount Sinai
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Eligible providers are * Internists and nurse practitioners * Provide care for patients with type 2 diabetes * Do not plan to relocate outside the practice in the next 6 months. Eligible patients * Have a diagnosis of type 2 diabetes mellitus \> 1 month confirmed by provider or the medical chart * Do not take statins, but their providers identify them as eligible for this medication * Are currently taking statins

Exclusion criteria

Ineligible patients * Have, in the providers' judgment, major barriers such as hearing impairment or dementia that would compromise their participation in shared decisionmaking; * are not available for follow-up 3 months after randomization * are pregnant * are under age 21

Design outcomes

Primary

MeasureTime frame
Morisky medication adherence scale3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026